New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
08:08 EDTCLSNCelsion's ThermoDox for liver cancer shows positive overall survival data
Celsion updated results from its retrospective analysis of the company's 701-patient HEAT Study of ThermoDox, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation in primary liver cancer. As of June 30, the latest quarterly Overall Survival analysis demonstrated that in 41% of the study patients, the combination of ThermoDox and optimized RFA provided a 57% improvement in OS compared to optimized RFA alone. Data from the latest HEAT Study post-hoc analysis continued to strongly suggest that ThermoDox may significantly improve OS compared to a RFA control in patients whose lesions undergo RFA treatment for 45 minutes or more.
News For CLSN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for CLSN

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use